Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

4 evidence topics · 11 sources

Summary: limitations of current therapies

No therapy directed at APOL1-mediated kidney disease is approved; the KDIGO 2025 conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”, and a 2021 Delphi consensus agreed that “No specific treatment is currently available”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, the primary kidney outcome occurred in 58.1% of participants with a high-risk genotype and 36.6% of those with a low-risk genotype (hazard ratio 1.88), with no interaction between APOL1 status and the randomized blood-pressure goal or antihypertensive drug. In the FSGS Clinical Trial, APOL1 genotype did not affect proteinuria response to cyclosporine or mycophenolate mofetil with dexamethasone, but participants with the high-risk genotype were more likely to progress to ESRD. In DUPLEX, sparsentan reduced proteinuria more than irbesartan without a significant difference in eGFR slope at 108 weeks, and the APOL1 high-risk subgroup comprised 14 participants. In a real-world cohort of 1,332 people with AMKD, 35.7% had a RAAS inhibitor fill or administration and 10.5% an SGLT2 inhibitor, and 45.7% had CKD stage 4 or 5.